髓源性抑制细胞在结直肠癌进展中的作用及治疗进展

摘要
图/表
参考文献(0)
相关文章 (15)

全文: PDF (812 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要髓源性抑制细胞（myeloidderived suppressor cells,MDSCs）是具有免疫抑制活性的未成熟髓细胞群体,在病理情况下,MDSCs的数量会大量增加。越来越多的证据表明,MDSCs是恶性肿瘤的基本特征之一,也是肿瘤治疗的潜在靶点。除了抑制宿主免疫系统对肿瘤的反应,帮助肿瘤细胞逃避免疫监视,MDSCs还能通过多种分子机制加速肿瘤的转移与复发。鉴于MDSCs是影响结直肠癌转移和预后的不良因素,本文综述了MDSCs促进结直肠癌发展不同阶段的潜在机制,并回顾了MDSCs在结直肠癌免疫治疗中的应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	蔡婧珊
	夏雪莉
	王胜军

关键词 ：结直肠癌, 髓源性抑制细胞, 免疫抑制, 循环肿瘤细胞, 转移前生态位, 靶向免疫治疗

收稿日期: 2021-06-08

基金资助:江苏省卫生健康委科研项目（K2019019）；江苏省医学重点人才项目（ZDRCB2016018）；江苏省研究生科研创新计划（KYCX21_3403）

通讯作者: 王胜军（通讯作者）,教授,博士生导师,E-mail:sjwjs@ujs.edu.cn

作者简介: 蔡婧珊（1996—）,女,硕士研究生

引用本文:

蔡婧珊,夏雪莉,王胜军. 髓源性抑制细胞在结直肠癌进展中的作用及治疗进展[J]. 江苏大学学报:医学版, 2022, 22(1): 84-87,92.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2022/V22/I1/84

［1］Onyoh EF, Hsu WF, Chang LC, et al. The rise of colorectal cancer in asia: epidemiology, screening, and management［J］. Curr Gastroenterol Rep, 2019, 21(8): 36.

［2］Sieminska I, Baran J. Myeloidderived suppressor cells in colorectal cancer［J］. Front Immunol, 2020, 11: 1526.

［3］Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice［J］. J Clin Invest, 2008, 118(7): 2516-2525.

［4］Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer［J］. Clin Cancer Res, 2014, 20(7): 1891-1899.

［5］Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloidderived suppressor cell nomenclature and characterization standards［J］. Nat Commun, 2016, 7: 12150.

［6］Wang Y, Yin K, Tian J, et al. Granulocytic myeloidderived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9［J］. Adv Sci (Weinh), 2019, 6(18): 1901278.

［7］Xu P, He H, Gu Y, et al. Surgical trauma contributes to progression of colon cancer by downregulating CXCL4 and recruiting MDSCs［J］. Exp Cell Res, 2018, 370(2): 692-698.

［8］De Cicco P, Ercolano G, Ianaro A. Thenew era of cancer immunotherapy: targeting myeloidderived suppressor cells to overcome immune evasion［J］. Front Immunol, 2020, 11: 1680.

［9］DiazMontero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy［J］. Cancer Immunol Immunother, 2009, 58(1): 49-59.

［10］Ouyang LY, Wu XJ, Ye SB, et al. Tumorinduced myeloidderived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer［J］. J Transl Med, 2015, 13: 47.

［11］Siemińska I, Poljańska E, Baran J. Granulocytes and cells of granulocyte originthe relevant players in colorectal cancer［J］. Int J Mol Sci, 2021, 22(7): 3801.

［12］Dufait I, Schwarze JK, Liechtenstein T, et al. Ex vivo generation of myeloidderived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer［J］. Oncotarget, 2015, 6(14): 12369-12382.

［13］Steggerda SM, Bennett MK, Chen J, et al. Inhibition of arginase by CB1158 blocks myeloid cellmediated immune suppression in the tumor microenvironment［J］. J Immunother Cancer, 2017, 5(1): 101.

［14］Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer［J］. Nat Med, 2007, 13(7): 828-835.

［15］Deng J, Li J, Sarde A, et al. Hypoxiainduced VISTA promotes the suppressive function of myeloidderived suppressor cells in the tumor microenvironment［J］. Cancer Immunol Res, 2019, 7(7): 1079-1090.

［16］Kumar V, Cheng P, Condamine T, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumorassociated macrophage differentiation［J］. Immunity, 2016, 44(2): 303-315.

［17］Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis［J］. Trends Cell Biol, 2019, 29(3): 212-226.

［18］Yang L, Huang J, Ren X, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr1+CD11b+ myeloid cells that promote metastasis［J］. Cancer Cell, 2008, 13(1): 23-35.

［19］Ye TH, Yang FF, Zhu YX, et al. Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis［J］. Cell Death Dis, 2017, 8(1): e2534.

［20］Vetsika EK, Koukos A, Kotsakis A. Myeloidderived suppressor cells: major figures that shape the immunosuppressive and angiogenic network in cancer［J］. Cells, 2019, 8(12): 1647.

［21］Hiratsuka S, Goel S, Kamoun WS, et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via Eselectin upregulation［J］. Proc Natl Acad Sci U S A, 2011, 108(9): 3725-3730.

［22］Trovato R, Canè S, Petrova V, et al. The engagement between MDSCs and metastases: partners in crime［J］. Front Oncol, 2020, 10: 165.

［23］Sprouse ML, Welte T, Boral D, et al. PMNMDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal signaling［J］. Int J Mol Sci, 2019, 20(8): 1916.

［24］Liu Q, Liao Q, Zhao Y. Myeloidderived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance［J］. Med Hypotheses, 2016, 87: 34-39.

［25］Liu Y, Cao X. Characteristics and significance of the premetastatic niche［J］. Cancer Cell, 2016, 30(5): 668-681.

［26］Wang D, Sun H, Wei J, et al. CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer［J］. Cancer Res, 2017, 77(13): 3655-3665.

［27］Zeng D, Wang M, Wu J, et al. Immunosuppressive microenvironment revealed by immune cell landscape in premetastatic liver of colorectal cancer［J］. Front Oncol, 2021, 11: 620688.

［28］Kitamura T, Fujishita T, Loetscher P, et al. Inactivation of chemokine (CC motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model［J］. Proc Natl Acad Sci U S A, 2010, 107(29): 13063-13068.

［29］Ren X, Xiao J, Zhang W, et al. Inhibition of CCL7 derived from MoMDSCs prevents metastatic progression from latency in colorectal cancer［J］. Cell Death Dis, 2021, 12(5): 484.

［30］Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOXBevacizumab drug treatment regimen［J］. Cancer Res, 2016, 76(18): 5241-5252.

［31］Yamagishi H, Kuroda H, Imai Y, et al. Molecular pathogenesis of sporadic colorectal cancers［J］. Chin J Cancer, 2016, 35: 4.

［32］Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy［J］. Genome Biol, 2015, 16(1): 64.

［33］Lichtenstern CR, Ngu RK, Shalapour S, et al. Immunotherapy, inflammation and colorectal cancer［J］. Cells, 2020, 9(3): 618.